IMU Biosciences joins NVIDIA Inception Programme to Accelerate AI-Driven Precision Medicine

London, UK, 3 October 2024 — IMU Biosciences is delighted to announce that it has been accepted into the NVIDIA Inception Programme, an initiative designed to support promising startups making advancements in AI, machine learning and data sciences.

This partnership will provide IMU Biosciences with access to NVIDIA's state-of-the-art technology and expertise, further enhancing its ability to use AI to translate vast system-level immune data into actionable insights and tools to advance precision medicine.

Key benefits of the partnership include:

Jeremy Mason, Chief Information Officer of IMU Biosciences, commented: "I’m thrilled to announce that IMU Biosciences has been accepted into the NVIDIA Inception Program—a milestone that truly underscores our unwavering commitment to innovation. This partnership empowers us to leverage state-of-the-art machine learning hardware and cutting-edge techniques, accelerating our mission to unlock the full potential of the immune system. With NVIDIA’s unparalleled resources and support, we are poised to elevate the development and training of precision medicine models capable of decoding the vast and varied datasets generated by our advanced immunophenotyping platform. The fusion of extraordinarily high-resolution immune system characterisation with access to bleeding-edge AI and machine learning technologies unlocks unprecedented possibilities for precision medicine."

About NVIDIA Inception

NVIDIA Inception is a program that supports startups revolutionising industries with technological advancements in AI and data sciences. The program provides critical go-to-market support, expertise, and technology for program members. Inception is a free program and does not require any equity from participating startups.

For more information, visit https://www.nvidia.com/inception/